ServisFirst Bancshares stock falls after net interest income misses expectations
Shares of ServisFirst Bancshares Inc. (SFBS), a bank with offices in the southern U.S., fell 7.5% after hours on Monday after the company reported third-quarter net interest income that came in below Wall Street's expectations. The bank reported net interest income of $99.7 million, below FactSet estimates for $102.5 million. "Net interest income was negatively impacted by the continued narrowing in net interest spread due to Federal Reserve increases in interest rates over the last year," the company said. The bank earned 98 cents a share during the period, compared with FactSet forecasts for 96 cents. Loans grew 3%, while total deposits came in at $13.1 billion, compared with around $11 billion in the same quarter last year. Chief Financial Officer Bud Foshee said in a statement that "loan pipelines and activity are beginning to rebuild, which should improve profitability in coming quarters."
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-16-23 1905ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks